RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

November 1, 2026

Conditions
HIVStimulant Use DisorderJustice Involved PopulationsHIV Prevention
Interventions
DEVICE

DynamiCare

DynamiCare is a mobile contingency management (CM) platform. Participants randomized to this intervention receive access to the DynamiCare app, an FDA-approved mobile application that delivers CM through features such as at-home saliva drug testing, appointment check-ins, and incentives for healthy behaviors. The app is designed to promote substance use reduction and engagement in care by providing financial rewards for meeting health-related goals. The intervention aims to improve initiation and retention in HIV prevention or treatment (PrEP or ART), reduce stimulant use, and enhance overall health outcomes among justice-involved individuals.

BEHAVIORAL

Patient Navigation (PN)

Participants work with a trained patient navigator (PN) who provides individualized support, assists with linkage to medical and social services, and helps address barriers to care. The PN meets with participants weekly during the first month and biweekly thereafter to conduct a comprehensive needs assessment and provide tailored support. This includes assistance with obtaining housing, identification, insurance, transportation, and linkage to health and social services such as HIV prevention or treatment (PrEP/ART), substance use disorder treatment, and other community-based care. The navigation protocol follows established procedures from prior studies (e.g., ACTION). All participants receive a smartphone to support communication and appointment coordination.

Trial Locations (2)

75235

Parkland County Hospital, Dallas

06520

Yale University, New Haven

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT07136363 - RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry | Biotech Hunter | Biotech Hunter